

# Michael Houghton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8982326/publications.pdf>

Version: 2024-02-01

180  
papers

23,465  
citations

9786

73  
h-index

7745

150  
g-index

190  
all docs

190  
docs citations

190  
times ranked

10289  
citing authors

#	ARTICLE	IF	CITATIONS
1	Binding of Hepatitis C Virus to CD81. <i>Science</i> , 1998, 282, 938-941.	12.6	1,814
2	Detection of Antibody to Hepatitis C Virus in Prospectively Followed Transfusion Recipients with Acute and Chronic Non-A, Non-B Hepatitis. <i>New England Journal of Medicine</i> , 1989, 321, 1494-1500.	27.0	1,717
3	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994, 19, 1321-1324.	7.3	962
4	Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease. <i>Hepatology</i> , 1991, 14, 381-388.	7.3	829
5	Analysis of a Successful Immune Response against Hepatitis C Virus. <i>Immunity</i> , 1999, 10, 439-449.	14.3	758
6	Structure, sequence and expression of the hepatitis delta ( $\delta$ ) viral genome. <i>Nature</i> , 1986, 323, 508-514.	27.8	751
7	Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. <i>Virology</i> , 1991, 180, 842-848.	2.4	641
8	Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.. <i>Journal of Clinical Investigation</i> , 1996, 98, 706-714.	8.2	617
9	Memory CD8 <sup>+</sup> T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection. <i>Journal of Experimental Medicine</i> , 2003, 197, 1645-1655.	8.5	591
10	Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. <i>Lancet</i> , The, 1991, 337, 317-319.	13.7	545
11	Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 1711-1715.	7.1	434
12	The Outcome of Hepatitis C Virus Infection Is Predicted by Escape Mutations in Epitopes Targeted by Cytotoxic T Lymphocytes. <i>Immunity</i> , 2001, 15, 883-895.	14.3	376
13	Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 2755-2759.	7.1	338
14	A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 1759-1763.	7.1	338
15	T-lymphocyte response to hepatitis C virus in different clinical courses of infection. <i>Gastroenterology</i> , 1993, 104, 580-587.	1.3	331
16	Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif.. <i>Journal of Clinical Investigation</i> , 1995, 95, 521-530.	8.2	310
17	Prospects for a vaccine against the hepatitis C virus. <i>Nature</i> , 2005, 436, 961-966.	27.8	301
18	HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release.. <i>Journal of Clinical Investigation</i> , 1995, 96, 2311-2321.	8.2	300

#	ARTICLE	IF	CITATIONS
19	Vertical transmission of hepatitis C virus. <i>Lancet, The</i> , 1991, 338, 17-18.	13.7	285
20	Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. <i>Journal of Virology</i> , 1997, 71, 6011-6019.	3.4	285
21	Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.. <i>Journal of Clinical Investigation</i> , 1996, 98, 1432-1440.	8.2	285
22	A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. <i>Cancer</i> , 1991, 67, 429-433.	4.1	283
23	The way forward in HCV treatment â€” finding the right path. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 991-1000.	46.4	267
24	Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18544-18549.	7.1	266
25	Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. <i>Journal of Virology</i> , 1996, 70, 7092-7102.	3.4	258
26	Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C.. <i>Journal of Experimental Medicine</i> , 1993, 178, 17-25.	8.5	246
27	Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. <i>Lancet, The</i> , 1990, 335, 873-874.	13.7	240
28	Hepatitis C antibody and chronic liver disease in haemophilia. <i>Lancet, The</i> , 1990, 335, 1117-1119.	13.7	234
29	The Hepatitis C Virus Encodes a Serine Protease Involved in Processing of the Putative Nonstructural Proteins from the Viral Polyprotein Precursor. <i>Biochemical and Biophysical Research Communications</i> , 1993, 192, 399-406.	2.1	221
30	Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. <i>Journal of Virology</i> , 1993, 67, 6753-6761.	3.4	213
31	Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. <i>Vaccine</i> , 2010, 28, 6367-6373.	3.8	208
32	Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. <i>Hepatology</i> , 2001, 33, 1479-1487.	7.3	206
33	Structure-Function Analysis of Hepatitis C Virus Envelope-CD81 Binding. <i>Journal of Virology</i> , 2000, 74, 4824-4830.	3.4	205
34	Association of hepatitis C virus envelope proteins with exosomes. <i>European Journal of Immunology</i> , 2004, 34, 2834-2842.	2.9	178
35	A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. <i>Nucleic Acids Research</i> , 1989, 17, 10367-10372.	14.5	172
36	Hepatitis C virus antigen in hepatocytes: Immunomorphologic detection and identification. <i>Gastroenterology</i> , 1992, 103, 622-629.	1.3	162

#	ARTICLE	IF	CITATIONS
37	A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans. <i>PLoS ONE</i> , 2013, 8, e59776.	2.5	151
38	Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon- $\lambda$ 2b. <i>Hepatology</i> , 1993, 18, 1300-1305.	7.3	149
39	Association of multispecific CD4+ response to hepatitis C and severity of recurrence after liver transplantation. <i>Gastroenterology</i> , 1999, 117, 926-932.	1.3	147
40	Immune responses to plasmid DNA encoding the hepatitis C virus core protein. <i>Journal of Virology</i> , 1995, 69, 5859-5863.	3.4	146
41	Complex Processing and Protein:Protein Interactions in the E2:NS2 Region of HCV. <i>Virology</i> , 1994, 204, 114-122.	2.4	143
42	Antibody response to core, envelope and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients. <i>Hepatology</i> , 1993, 18, 497-502.	7.3	142
43	Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. <i>Immunological Reviews</i> , 2011, 239, 99-108.	6.0	141
44	Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells. <i>Virology</i> , 1992, 188, 819-830.	2.4	139
45	Hepatitis C Virus-specific Cytolytic T Lymphocyte and T Helper Cell Responses in Seronegative Persons. <i>Journal of Infectious Diseases</i> , 1997, 176, 859-866.	4.0	139
46	A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. <i>Journal of Virology</i> , 1993, 67, 4365-4368.	3.4	139
47	High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. <i>Hepatology</i> , 1998, 28, 1117-1120.	7.3	134
48	Hepatitis C virus core and E2 protein expression in transgenic mice. <i>Hepatology</i> , 1997, 25, 719-727.	7.3	133
49	The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. <i>Emerging Microbes and Infections</i> , 2014, 3, 1-12.	6.5	129
50	Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus. <i>Journal of Clinical Microbiology</i> , 1992, 30, 3220-3224.	3.9	128
51	Use of a signature nucleotide sequence of hepatitis C virus for detection of viral RNA in human serum and plasma. <i>Journal of Clinical Microbiology</i> , 1991, 29, 2528-2534.	3.9	127
52	Small Interfering RNA-Mediated Inhibition of Hepatitis C Virus Replication in the Human Hepatoma Cell Line Huh-7. <i>Journal of Virology</i> , 2003, 77, 810-812.	3.4	125
53	Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. <i>Virus Research</i> , 2018, 248, 53-62.	2.2	124
54	Synthesis and Characterization of a Native, Oligomeric Form of Recombinant Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein. <i>Journal of Virology</i> , 2004, 78, 10328-10335.	3.4	117

#	ARTICLE	IF	CITATIONS
55	The long and winding road leading to the identification of the hepatitis C virus. <i>Journal of Hepatology</i> , 2009, 51, 939-948.	3.7	117
56	Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine. <i>Journal of Immunology</i> , 2001, 166, 3589-3598.	0.8	108
57	IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza. <i>PLoS Pathogens</i> , 2014, 10, e1004556.	4.7	108
58	Activation of the <i>grp78</i> and <i>grp94</i> Promoters by Hepatitis C Virus E2 Envelope Protein. <i>Journal of Virology</i> , 1999, 73, 3718-3722.	3.4	106
59	Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV. <i>Journal of Virology</i> , 1995, 69, 32-38.	3.4	105
60	Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers. <i>Nucleic Acids Research</i> , 1990, 18, 4626-4626.	14.5	103
61	Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. <i>Journal of Virology</i> , 1997, 71, 2241-2251.	3.4	101
62	Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX <sup>®</sup> vaccine: A phase I study in healthy volunteers. <i>Hum Vaccin</i> , 2009, 5, 151-157.	2.4	100
63	Characterization of Antibodies Induced by Vaccination with Hepatitis C Virus Envelope Glycoproteins. <i>Journal of Infectious Diseases</i> , 2010, 202, 862-866.	4.0	99
64	Liver-Derived Hepatitis C Virus(HCV)-Specific CD4+ T Cells Recognize Multiple HCV Epitopes and Produce Interferon Gamma. <i>Hepatology</i> , 2000, 32, 597-603.	7.3	96
65	Discovery of the hepatitis C virus. <i>Liver International</i> , 2009, 29, 82-88.	3.9	92
66	Vaccine-Induced Cross-Genotype Reactive Neutralizing Antibodies Against Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2011, 204, 1186-1190.	4.0	91
67	Intrahepatic Genetic Inoculation of Hepatitis C Virus RNA Confers Cross-Protective Immunity. <i>Journal of Virology</i> , 2001, 75, 7142-7148.	3.4	90
68	Hepatitis C Virus and eliminating post-transfusion hepatitis. <i>Nature Medicine</i> , 2000, 6, 1082-1086.	30.7	89
69	Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. <i>Scientific Reports</i> , 2019, 9, 12392.	3.3	88
70	Hepatitis C viral cDNA clones isolated from a healthy carrier donor implicated in post-transfusion non-A, non-B hepatitis. <i>Gene</i> , 1990, 91, 287-291.	2.2	86
71	Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis. <i>Hepatology</i> , 1992, 15, 187-190.	7.3	84
72	5' end-dependent translation initiation of hepatitis C viral RNA and the presence of putative positive and negative translational control elements within the 5' untranslated region. <i>Virology</i> , 1992, 191, 889-899.	2.4	82

#	ARTICLE	IF	CITATIONS
73	Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. <i>Vaccine</i> , 2007, 25, 7773-7784.	3.8	81
74	Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1215.	4.8	80
75	HCV testing in low-risk population. <i>Lancet, The</i> , 1990, 336, 695.	13.7	75
76	Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. <i>Virology</i> , 2005, 332, 438-453.	2.4	74
77	Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. <i>Journal of General Virology</i> , 2000, 81, 2451-2459.	2.9	74
78	Characterization of liver T-cell receptor $\gamma\delta$ + T cells obtained from individuals chronically infected with hepatitis C virus (HCV): Evidence for these T cells playing a role in the liver pathology associated with HCV infections. <i>Hepatology</i> , 2001, 33, 1312-1320.	7.3	73
79	Prevalence of Anti-HCV Antibody in Blood Donors in the Tokyo Area. <i>Vox Sanguinis</i> , 1990, 59, 86-88.	1.5	71
80	Evaluation of Hepatitis C Virus Glycoprotein E2 for Vaccine Design: an Endoplasmic Reticulum-Retained Recombinant Protein Is Superior to Secreted Recombinant Protein and DNA-Based Vaccine Candidates. <i>Journal of Virology</i> , 2000, 74, 6885-6892.	3.4	70
81	Cationic microparticles are a potent delivery system for a HCV DNA vaccine. <i>Vaccine</i> , 2004, 23, 672-680.	3.8	70
82	Early Antihepatitis C Virus Response with Second-Generation C200/C22 ELISA. <i>Vox Sanguinis</i> , 1992, 62, 208-212.	1.5	69
83	Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2014, 210, 717-727.	4.0	68
84	Hepatitis C virus replication in "autoimmune" chronic hepatitis. <i>Journal of Hepatology</i> , 1991, 13, 364-367.	3.7	63
85	Recombinant Hepatitis C Virus Envelope Glycoprotein Vaccine Elicits Antibodies Targeting Multiple Epitopes on the Envelope Glycoproteins Associated with Broad Cross-Neutralization. <i>Journal of Virology</i> , 2014, 88, 14278-14288.	3.4	60
86	Enhanced Sensitivity of a Second Generation ELISA for Antibody to Hepatitis C Virus. <i>Vox Sanguinis</i> , 1992, 62, 213-217.	1.5	55
87	Immunization of Human Volunteers With Hepatitis C Virus Envelope Glycoproteins Elicits Antibodies That Cross-Neutralize Heterologous Virus Strains. <i>Journal of Infectious Diseases</i> , 2011, 204, 811-813.	4.0	55
88	Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers. <i>Hepatology</i> , 2013, 58, 1907-1917.	7.3	55
89	Induction of Broad CD4 <sup>+</sup> and CD8 <sup>+</sup> T-Cell Responses and Cross-Neutralizing Antibodies against Hepatitis C Virus by Vaccination with Th1-Adjuvanted Polypeptides Followed by Defective Alphaviral Particles Expressing Envelope Glycoproteins gpE1 and gpE2 and Nonstructural Proteins 3, 4, and 5. <i>Journal of Virology</i> , 2008, 82, 7492-7503.	3.4	52
90	Induction in vitro of a primary human antiviral cytotoxic T cell response. <i>European Journal of Immunology</i> , 1995, 25, 627-630.	2.9	51

#	ARTICLE	IF	CITATIONS
91	Sequence variation in hepatitis C viral isolates. <i>Journal of Hepatology</i> , 1991, 13, S6-S14.	3.7	49
92	Differential Serum Levels of Eosinophilic Eotaxins in Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, and Autoimmune Hepatitis. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 204-214.	1.2	49
93	Expression of Human CD81 in Transgenic Mice Does Not Confer Susceptibility to Hepatitis C Virus Infection. <i>Virology</i> , 2002, 304, 187-196.	2.4	47
94	A human ether-Å <sub>i</sub> -go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity. <i>Toxicology Letters</i> , 2014, 230, 382-392.	0.8	47
95	Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. <i>Journal of Virology</i> , 1994, 68, 4420-4426.	3.4	47
96	Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. <i>Journal of General Virology</i> , 2006, 87, 2253-2262.	2.9	45
97	Antibody to the hepatitis C virus in acute hepatitis and chronic liver diseases in Japan. <i>Liver</i> , 2008, 11, 65-70.	0.1	45
98	Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells. <i>PLoS Pathogens</i> , 2020, 16, e1008515.	4.7	42
99	Folding of Hepatitis C Virus E1 Glycoprotein in a Cell-Free System. <i>Journal of Virology</i> , 2001, 75, 11205-11217.	3.4	41
100	Progress towards a hepatitis C virus vaccine. <i>Emerging Microbes and Infections</i> , 2013, 2, 1-7.	6.5	41
101	Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome. <i>Cytokine</i> , 2016, 78, 27-36.	3.2	40
102	Elevated Serum Alanine Aminotransferase Levels in Blood Donors: The Contribution of Hepatitis C Virus. <i>Annals of Internal Medicine</i> , 1991, 115, 882-884.	3.9	39
103	Group specific sequences and conserved secondary structures at the 3' end of HCV genome and its implication for viral replication. <i>Nucleic Acids Research</i> , 1992, 20, 3520-3520.	14.5	39
104	Perspectives for a vaccine against hepatitis C virus. <i>Journal of Hepatology</i> , 1999, 31, 259-263.	3.7	39
105	A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 362-373.	5.4	39
106	Variable Patterns of Programmed Death-1 Expression on Fully Functional Memory T Cells after Spontaneous Resolution of Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2008, 82, 5109-5114.	3.4	38
107	Structure and Function of the Hepatitis C Virus Envelope Glycoproteins E1 and E2: Antiviral and Vaccine Targets. <i>ACS Infectious Diseases</i> , 2016, 2, 749-762.	3.8	38
108	Hepatitis C Virus-Specific CD4+T Cell Response after Liver Transplantation Occurs Early, Is Multispecific, Compartmentalizes to the Liver, and Does Not Correlate with Recurrent Disease. <i>Journal of Infectious Diseases</i> , 2001, 183, 1187-1194.	4.0	37

#	ARTICLE	IF	CITATIONS
109	Fabrication of flexible self-standing all-cellulose nanofibrous composite membranes for virus removal. <i>Carbohydrate Polymers</i> , 2016, 143, 9-17.	10.2	36
110	Identification of the Major, Parenteral Non-A, Non-B Hepatitis Agent (Hepatitis C Virus) Using a Recombinant cDNA Approach. <i>Seminars in Liver Disease</i> , 1992, 12, 279-288.	3.6	34
111	Enhanced Activation of Memory, but Not Na <sup>+</sup> ve, B Cells in Chronic Hepatitis C Virus-Infected Patients with Cryoglobulinemia and Advanced Liver Fibrosis. <i>PLoS ONE</i> , 2013, 8, e68308.	2.5	34
112	Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. <i>Journal of Virology</i> , 2018, 92, .	3.4	34
113	Hepatitis C antibody in patients with chronic liver disease and hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1130-1133.	2.3	33
114	Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. <i>Journal of Virology</i> , 2017, 91, .	3.4	33
115	Glycogen synthase kinase 3 <sup>β</sup> inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism. <i>Scientific Reports</i> , 2017, 7, 2495.	3.3	32
116	Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). <i>Journal of Hepatology</i> , 2005, 42, 499-504.	3.7	30
117	Characterization of an Immunodominant Antigenic Site on GB Virus C Glycoprotein E2 That Is Involved in Cell Binding. <i>Journal of Virology</i> , 2006, 80, 12131-12140.	3.4	29
118	Arylacetamide deacetylase: A novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production. <i>Journal of Hepatology</i> , 2013, 59, 336-343.	3.7	29
119	Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus. <i>Journal of Virology</i> , 2017, 91, .	3.4	29
120	Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination. <i>Journal of Infectious Diseases</i> , 2015, 212, 137-146.	4.0	28
121	Modeling the human Na <sup>v</sup> 1.5 sodium channel: structural and mechanistic insights of ion permeation and drug blockade. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2301-2324.	4.3	28
122	Detailed Computational Study of the Active Site of the Hepatitis C Viral RNA Polymerase to Aid Novel Drug Design. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 3031-3043.	5.4	27
123	Hepatitis C Virus: Structure, Protein Products and Processing of the Polyprotein Precursor. <i>Current Studies in Hematology and Blood Transfusion</i> , 1994, 61, 1-11.	0.2	26
124	Hepatitis C virus antibodies in acute icteric and chronic non-A, non-B hepatitis. <i>Gastroenterology</i> , 1991, 101, 1117-1119.	1.3	25
125	Minimum data elements for research reports on CFS. <i>Brain, Behavior, and Immunity</i> , 2012, 26, 401-406.	4.1	25
126	Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. <i>Liver Transplantation</i> , 2016, 22, 324-332.	2.4	25



#	ARTICLE	IF	CITATIONS
127	Vaccine adjuvants â€œ understanding molecular mechanisms to improve vaccines. Swiss Medical Weekly, 2014, 144, w13940.	1.6	24
128	Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins. Vaccines, 2019, 7, 204.	4.4	23
129	SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. Vaccine, 2021, 39, 5769-5779.	3.8	23
130	Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA. Drug Discovery Today, 2015, 20, 548-561.	6.4	22
131	An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions. Journal of Visualized Experiments, 2016, , .	0.3	22
132	Hepatitis C Virus Heteroduplex Tracking Assay for Genotype Determination Reveals Diverging Genotype 2 Isolates in Italian Hemodialysis Patients. Journal of Clinical Microbiology, 1998, 36, 227-233.	3.9	22
133	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. Journal of Hepatology, 2019, 70, 593-602.	3.7	20
134	Hepatitis C virus markers in patients with longâ€term biochemical and histological remission of chronic hepatitis. Liver, 1994, 14, 65-70.	0.1	19
135	<i><sc>HCV E1E</sc>2â€<sc>MF</sc>59</i> vaccine in chronic hepatitis <sc>C</sc> patients treated with <sc>PEG</sc>â€<sc>IFN</sc>1±2a and <sc>R</sc>ibavirin: a randomized controlled trial. Journal of Viral Hepatitis, 2014, 21, 458-465.	2.0	19
136	Hepatitis C: The next 25 years. Antiviral Research, 2014, 110, 77-78.	4.1	19
137	Hepatitis C Virus: 30 Years after Its Discovery. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a037069.	6.2	18
138	Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1. Cell Chemical Biology, 2020, 27, 780-792.e5.	5.2	18
139	High prevalence of G1 and G2 TT-virus infection in subjects with high and low blood exposure risk: identification of G4 isolates in Italy. Journal of Hepatology, 1999, 31, 990-996.	3.7	15
140	Quantification of the number of cytotoxic T cells specific for an immunodominant HCV-specific CTL epitope primed by DNA immunization. Vaccine, 2000, 18, 1962-1968.	3.8	15
141	A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. Journal of Hepatology, 2019, 70, 1082-1092.	3.7	15
142	A structure-based computational workflow to predict liability and binding modes of small molecules to hERG. Scientific Reports, 2020, 10, 16262.	3.3	15
143	Immunization of woodchucks with adjuvanted sHDAg (p24): immune response and outcome following challenge. Vaccine, 2004, 22, 457-466.	3.8	14
144	A Computational Model for Overcoming Drug Resistance Using Selective Dual-Inhibitors for Aurora Kinase A and Its T217D Variant. Molecular Pharmaceutics, 2013, 10, 4572-4589.	4.6	14

#	ARTICLE	IF	CITATIONS
145	A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021, 73, 1105-1116.	7.3	14
146	No Evidence for XMRV Nucleic Acids, Infectious Virus or Anti-XMRV Antibodies in Canadian Patients with Chronic Fatigue Syndrome. <i>PLoS ONE</i> , 2011, 6, e27870.	2.5	14
147	CD4 T Lymphocyte Proliferative Responses to Hepatitis C Virus (HCV) Antigens in Patients Coinfected with HCV and Human Immunodeficiency Virus Who Responded to Anti-HCV Treatment. <i>Journal of Infectious Diseases</i> , 2002, 186, 302-311.	4.0	13
148	A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. <i>Journal of Virology</i> , 2019, 93, .	3.4	13
149	Comparison of secretion of a hepatitis C virus glycoprotein in <i>Saccharomyces cerevisiae</i> and <i>Kluyveromyces lactis</i> . <i>Research in Microbiology</i> , 1999, 150, 179-187.	2.1	12
150	Antibody response to core, envelope and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients. <i>Hepatology</i> , 1993, 18, 497-502.	7.3	12
151	Long term treatment of chronic hepatitis C with interferon alfa-2b: disappearance of HCV-RNA in a pilot study of eight haemophilia patients.. <i>Gut</i> , 1993, 34, S124-S125.	12.1	11
152	A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry. <i>ACS Infectious Diseases</i> , 2016, 2, 872-881.	3.8	10
153	A computational approach for predicting off-target toxicity of antiviral ribonucleoside analogues to mitochondrial RNA polymerase. <i>Journal of Biological Chemistry</i> , 2018, 293, 9696-9705.	3.4	10
154	Vertical Transmission of Hepatitis C Virus. <i>Obstetrical and Gynecological Survey</i> , 1992, 47, 31-32.	0.4	9
155	Priming of hepatitis C virus-specific cytotoxic t lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA. <i>Hepatology</i> , 2000, 31, 1327-1333.	7.3	9
156	An Inactivated Hepatitis C Virus Vaccine on the Horizon?. <i>Gastroenterology</i> , 2013, 145, 285-288.	1.3	8
157	PROSPECTS FOR A HEPATITIS C VIRUS VACCINE. <i>Clinics in Liver Disease</i> , 1999, 3, 901-915.	2.1	7
158	Use of recombinant HCV antigen in the serodiagnosis of hepatitis C virus infection: Significant improvement in HCV antibody detection as compared with the first generation HCV C100-3 ELISA and the synthetic peptide EIA tests. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, S33-S39.	2.8	5
159	Rational Drug Design. <i>International Journal of Computational Models and Algorithms in Medicine</i> , 2014, 4, 59-85.	0.4	5
160	Sociodemographic risk factors for hepatitis C virus infection in a prospective cohort study of 257 persons in Canada who inject drugs. <i>Canadian Liver Journal</i> , 2020, 3, 276-285.	0.9	5
161	Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19. <i>BMC Pharmacology &amp; Toxicology</i> , 2021, 22, 61.	2.4	5
162	A novel method for detection of IFN-lambda 3 binding to cells for quantifying IFN-lambda receptor expression. <i>Journal of Immunological Methods</i> , 2017, 445, 15-22.	1.4	4

#	ARTICLE	IF	CITATIONS
163	Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 6566-6578.	5.4	4
164	The Hepatitis C Virus: Genetic Organization, Persistence, and Vaccine Strategies. , 1994, , 33-37.		4
165	7 Humoral response to hepatitis C virus. <i>Biomedical Research Reports</i> , 2000, 2, 125-145.	0.3	3
166	Effect of IL-12 on T-cell immune responses in patients with chronic HCV infection. <i>Apmis</i> , 2000, 108, 531-538.	2.0	3
167	Application of Polymerase Chain Reaction to Hepatitis C Virus Research and Diagnostics. <i>Frontiers of Virology</i> , 1992, , 86-100.	0.6	3
168	Rabbit-derived anti-HD antibodies for HDAg immunoblotting. <i>Journal of Hepatology</i> , 1991, 13, S130-S133.	3.7	2
169	The Discovery of the Hepatitis C Virus. <i>Topics in Medicinal Chemistry</i> , 2019, , 19-27.	0.8	2
170	Chimp Virus Makes a Savvy Vaccine Vector. <i>Science Translational Medicine</i> , 2012, 4, 115fs1.	12.4	1
171	Three isn't the magic number. <i>Nature Medicine</i> , 2013, 19, 807-807.	30.7	1
172	Progress toward approval of an HCV vaccine. <i>Canadian Liver Journal</i> , 2018, 1, 130-138.	0.9	1
173	Hepatitis C Vaccines. , 2018, , 375-385.e5.		1
174	Hepatitis C virus vaccines. , 2008, , 1187-1199.		1
175	Seroepidemiology of Hepatitis C Among Drug Users at a Detoxification Center in Southeast China. <i>Hepatitis Monthly</i> , 2020, 20, .	0.2	1
176	Hepatitis C vaccines. , 2013, , 1074-1084.		0
177	Towards the Control of Hepatitis C. , 2016, , 3-14.		0
178	Progress toward approval of an HCV vaccine. <i>Canadian Liver Journal</i> , 2018, , 1-9.	0.9	0
179	Hepatitis C Virus-specific Cytotoxic T Lymphocytes Restricted by HLA-A2 are Present in the Peripheral Blood of Patients with Chronic Hepatitis C. , 1994, , 190-194.		0
180	HCV-positive, HIV-1-negative Mothers Transmit HCV. , 1994, , 463-467.		0